News Desk, News Nation 360 : Surgical oncologists at Apollo Cancer Centre (ACC) have successfully treated a peritoneal surface cancer with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in India's first Robotic Cytoreductive Surgery (CRS), marking a significant advancement in medical science. Pseudomyxoma Peritonei (PMP), an aggressive appendix cancer, can now be treated with a minimally invasive, robotically assisted approach that offers patients a new standard of care that promotes quicker recovery and a higher quality of life. An appendix, uterus, ovaries, and a portion of the omentum were removed during surgery for a 51-year-old woman Subarna (name changed) who had ovarian masses. Subsequent investigation identified pseudomyxoma peritonei, an aggressive appendix cancer that had spread to the lining of the abdomen. She underwent minimally invasive robotic cytoreductive surgery to remove the cancer and surrounding tissue, including portions of her colon and omentum, because she still had cancer implants. To eradicate any microscopic cancer cells, heated chemotherapy was administered directly to the abdomen in addition to this surgery. In contrast to the open and highly invasive nature of this complex surgery, the robotic approach reduced her pain, blood loss, scarring, and discomfort. At her one-year follow-up, she is cancer-free after a quick recovery. When compared to open surgery, this minimally invasive robotic cytoreductive surgery (CRS) provided several benefits. The robotic method reduced pain, bleeding, scarring, and discomfort by using tiny incisions for the instruments. Furthermore, the removal of the tumour and the administration of heated chemotherapy only required one larger incision. The patient recovered and returned to their regular life more quickly as a result of this innovative approach. She is still cancer-free and in excellent health at the one-year follow-up, which emphasises the potential advantages of minimally invasive robotic surgery for difficult abdominal cancers. Dr Ajit Pai, Senior Consultant in Surgical Oncology and Robotic Surgery, at Apollo Cancer Centre, stated that While precise tumour resections using robotic CRS require proficiency with both traditional and robotic techniques, it offers a transformative approach. Patients whose cancer cells have limitedly spread to and implanted on the peritoneal surfaces may find this method to be a viable option due to its minimal access requirements, accelerated recovery, and reduced postoperative morbidity. The promising clinical outcome and the potential of this approach to enhance the quality of life for patients with peritoneal surface cancers, including those from gastric, ovarian, and colon cancers, excite them.
Pic - Courtesy
